SecurityCMPGY / Compass Group Plc (20449X302)
Institutional Owners19
Institutional Shares3,144,657
Institutional Value$ 1,283,052,000 USD

Institutional Stock Ownership and Shareholders

CMPGY / Compass Group Plc Institutional Ownership

Compass Group Plc (OTC:CMPGY) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,144,657 shares. Largest shareholders include Parametric Portfolio Associates Llc, Aristotle Capital Management, LLC, Silvercrest Asset Management Group Llc, Scout Investments, Inc., Geneva Advisors, LLC, Paradigm Asset Management Co Llc, Northroad Capital Management Llc, World Asset Management Inc, Chartwell Investment Partners, Llc, and Hartwell J M Limited Partnership.
Compass Group Plc (OTC:CMPGY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-06 13F-HR FTB Advisors, Inc. 359 181 -49.58 7 3 -57.14
2018-07-13 13F-HR HARTWELL J M LIMITED PARTNERSHIP 21,784 21,784 0.00 454 472 3.96
2018-08-13 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 1,680,340 1,821,915 8.43 35,010 39,444 12.66
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 7,401 7,487 1.16 151 160 5.96
2018-08-06 13F-HR Sonora Investment Management, LLC 70 70 0.00 1,458 2 -99.86
2018-07-18 13F-HR World Asset Management Inc 62,999 47,475 -24.64 1,313 1,014 -22.77
2018-08-15 13F-HR PARADIGM ASSET MANAGEMENT CO LLC 56,937 56,937 0.00 1,162,526 1,216,644 4.66
2018-08-08 13F-HR QUADRANT CAPITAL GROUP LLC 7,438 7,253 -2.49 146 146 0.00
2018-07-16 13F-HR SCOUT INVESTMENTS, INC. 154,172 146,944 -4.69 3,148 3,140 -0.25
2018-07-17 13F-HR Gemmer Asset Management LLC 99 76 -23.23 2 2 0.00
2018-08-14 13F-HR SILVERCREST ASSET MANAGEMENT GROUP LLC 151,589 154,782 2.11 3,158 3,351 6.11
2018-08-15 13F-HR GLENMEDE TRUST CO NA 2,972 0 -100.00 64 0 -100.00
2018-07-11 13F-HR Vigilant Capital Management, LLC 981 21
2018-08-09 13F-HR CHARTWELL INVESTMENT PARTNERS, LLC 23,253 497
2018-08-14 13F-HR Aristotle Capital Management, LLC 730,240 735,456 0.71 14,910 15,715 5.40
2018-07-26 13F-HR Lenox Wealth Management, Inc. 398 9
2018-08-08 13F-HR Private Capital Group, Llc 2,327 2,526 8.55 48 55 14.58
2018-07-16 13F-HR Lenox Wealth Advisors, Inc. 0 404 0 9
2016-11-14 13F-HR NORTHROAD CAPITAL MANAGEMENT LLC 193,086 56,856 -70.55 3,688 1,104 -70.07
2017-08-07 13F-HR Geneva Advisors, LLC 60,200 59,879 -0.53 1,136 1,264 11.27

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Compass Group (CMPGY) Reports On Adoption of IFRS 15 - Slideshow

2018-09-14 seekingalpha
The following slide deck was published by Compass Group Plc ADR in conjunction with this event.

British tycoon killed in Sydney seaplane crash leaves $72m to Oxfam

2018-08-22 smh.com.au
London: A tycoon killed with his family in a seaplane crash in the Hawkesbury River on New Year's Eve has left a £41 million ($72 million) fortune to the crisis-hit charity Oxfam, a British newspaper reported on Tuesday.

AWC order book seen to provide earnings visibility beyond 2020

2018-08-13 theedgemarkets
AWC Bhd (Aug 10, 78 sen) Maintain buy with a higher target price of RM1.04 from 78 sen: We remain bullish after our meeting with management. The change in government will not impede facility management business sentiments. Instead, AWC is poised to benefit from cost-tightening measures.

As Markets Refocus On Fundamentals, EQV Takes The Spotlight

2018-08-03 seekingalpha
Could we see an increased market focus on quality and valuation as the strong earnings upgrade cycle appears to fade?

Compass Diversified Holdings (CODI) CEO Elias Sabo Name on Q2 2018 Results - Earnings Call Transcript

2018-08-02 seekingalpha
Good morning. And welcome to Compass Diversified Holdings' 2018 Second Quarter Conference Call. Today's call is being recorded. All lines have been placed on mute. [Operator Instructions] At this time, I would like to turn the conference over to Leon Berman of the IGB Group for introductions and the reading of the Safe Harbor statement. Please go ahead, sir.

CUSIP: 20449X302